

**Title: Study on the mucosal and serological immune response to the Novel Coronavirus
(SARS-CoV-2) vaccines**

Renee WY Chan^{1,2,3,4*}, Shaojun Liu^{1,2,3,4}, Jonathan Y Cheung^{1,2,3,4}, Joseph GS Tsun^{1,2,3,4}, Kate C Chan^{1,2}, Kathy YY Chan^{1,2}, Genevieve PG Fung¹, Albert M Li^{1,2,4}, Hugh Simon Lam^{1,2*}

¹ Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

² Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

³ CUHK-UMCU Joint Research Laboratory of Respiratory Virus & Immunobiology, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR.

⁴ Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR.

*Corresponding Authors

Renee Wan Yi Chan, PhD, MPhil, BSc

Assistant Professor, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong

Corresponding Address: Lab D, 8/F Tower A, The Hong Kong Children's Hospital, Kowloon Bay, Kowloon, HONG KONG

Office Phone: 852+3513-3175

Office Fax: 852+2636-0020

Email: reneewy@cuhk.edu.hk

Hugh Simon Lam, BChir (Cantab), MB (Cantab), MD (CUHK), MRCPCH (UK), FHKCPaed,
FHKAM (Paediatrics), FRCPCH (UK)

Professor, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong
Kong

Corresponding Address: 6/F Lui Chee Woo Clinical Sciences Building

Office Phone: 852+3505-2851 Office Fax: 852+2636-0020

Email: hshslam@cuhk.edu.hk

1 **One Sentence Summary:**

2 mRNA vaccine (CoronaVac) elicits mucosal IgA and IgG in the nasal epithelial lining fluid
3 together with ELISA-detected anti-wild-type spike neutralizing antibodies as early as day 14 post
4 vaccination.

5
6 **Abstract**

7 Vaccines that elicit mucosal immune responses against SARS-CoV-2 could potentially be of
8 exceptional importance in providing first line defense at the site of viral entry. The serological
9 antibody response induced by SARS-CoV-2 vaccines have already been well characterized. In
10 order to understand the mucosal immune response profiles of SARS-CoV-2 vaccines, we
11 examined both the mucosal and systemic responses of subjects vaccinated by two different
12 vaccination platforms: mRNA (Comirnaty) and inactivated virus (CoronaVac). Serial nasal
13 epithelial lining fluid (NELF) and peripheral blood samples were collected in ten subjects who
14 had received CoronaVac and thirty-two subjects who had received Comirnaty. We quantified
15 IgA and IgG specific to SARS-CoV-2 S1 protein by ELISA in NELF and plasma samples. The
16 neutralization effect of these two sample types were evaluated by surrogate ACE-SARS-CoV-2
17 Spike protein ELISA. Only Comirnaty induced nasal SARS-CoV-2 S1 protein-specific (S1-
18 specific) IgA and IgG responses, which were evident as early as on 14 ± 2 days after the first
19 dose. The NELF samples of 72% of subjects became IgA+IgG+, while in 62.5% of subjects the
20 samples were neutralizing by 7 ± 2 days after the second dose. In 45% of the subjects their NELF
21 remained neutralizing 50 days after the booster of Comirnaty. In plasma, 91% and 100%
22 Comirnaty subjects possessed S1-specific IgA+IgG+ on 14 ± 2 days after the first dose and 7 ± 2
23 days after booster, respectively. The plasma collected on 7 ± 2 days after booster was 100%

24 neutralizing. The induction of S1-specific antibody by CoronaVac was IgG dominant, and 70%
25 of the subjects possessed S1-specific IgG by 7 ± 2 days after booster and were all neutralizing.
26 This study reveals that Comirnaty is able to induce S1-specific IgA and IgG response with
27 neutralizing activity in the nasal mucosa in addition to a consistent systemic response. The
28 clinical implications and the biological mechanism of an additional nasal immune response
29 induced by vaccines such as Comirnaty warrant further investigation.

30 INTRODUCTION

31 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes the
32 coronavirus disease 2019 (COVID-19) pandemic that has resulted in significant morbidity and a
33 global death toll of over 3 million (1).

34
35 Among the various COVID-19 vaccines currently authorized by the World Health Organization
36 (WHO), CoronaVac by Sinovac Biotech and BNT162b2 (aka Comirnaty) from Pfizer-BioNTech
37 have been approved for emergency use in Hong Kong. These two vaccines utilize different
38 technological platforms, namely inactivated whole virus and messenger RNA (mRNA) encoding
39 the full-length viral spike (S) protein modified by two proline mutations, respectively (2). The S-
40 protein of SARS-CoV-2 is composed of the subunits S1 and S2, with S1 bearing the receptor-
41 binding domain (RBD) that recognizes host angiotensin-converting enzyme 2 (ACE2) to initiate
42 viral entry (3, 4) and S2 being responsible for membrane fusion (3). Both vaccines have good
43 safety records with low prevalence of serious adverse events (5-7). CoronaVac has been shown
44 to prevent symptomatic COVID-19 in 51% of vaccinated healthcare workers, and an efficacy of
45 100% in preventing severe COVID-19 (8). Comirnaty is reported to be 95% effective in
46 preventing symptomatic COVID-19 with low incidence of serious adverse events (5).

47
48 Mechanistic properties of these novel vaccines in conferring immunity to combat COVID-19 are
49 beginning to emerge. It has been shown that by 14 days after the booster dose, recipients of
50 CoronaVac aged 18-50 years had seroconversion rates of 95.6% and 95.7% for S1-RBD IgG and
51 neutralizing antibodies, respectively (9). In comparison, specific IgG against S1 and RBD of
52 SARS-CoV-2 are detectable in serum at 21 days after the priming dose of Comirnaty, with 100%

53 seroconversion rate (10). Due to the differences in the study design, it would be difficult to
54 compare the seroconversion times for both SARS-CoV-2 S1 protein-specific (S1-specific) IgG
55 and SARS-CoV-2 neutralization between the two vaccines. It is also important to note that due to
56 differences in the stages of vaccine development, there is currently more research data available
57 for the mRNA vaccines (e.g., Comirnaty and Moderna) than inactivated viral vaccines (e.g.,
58 CoronaVac).

59
60 Comirnaty and Moderna elicit neutralizing antibody (NAb) responses that target the RBD
61 epitopes in the same manner as natural infections (11). Albeit at much lower titers than IgG
62 levels, the mRNA vaccines also induce IgM and IgA responses against S-protein and RBD in
63 plasma samples (11). In the sequence of seroconversion, IgM responses are first generated and
64 then class-switch converted to IgA and IgG (12). As detectable IgM levels after vaccinations are
65 often significantly lower and less sustained when compared to IgA and IgG levels, IgM is
66 suspected to have lesser importance in virus neutralization *in vivo* (11, 13). On the other hand,
67 serum RBD IgA from COVID-19 patients has been found to have more potent neutralization
68 potential than paired IgG (14). SARS-CoV-2 IgA can be sustainably elevated in serum or plasma
69 samples for over 2 months after Comirnaty vaccination (13). Thus, the importance of systemic
70 SARS-CoV-2 IgA in vaccine-induced immunity against COVID-19 warrants further validation
71 (13, 15).

72
73 Since SARS-CoV-2 infects the upper respiratory tract initially, local neutralizing antibodies
74 could provide substantial protection against infection. In saliva of COVID-19 patients, SARS-
75 CoV-2 IgA levels was found to be higher than IgG, with neutralization activity correlating with

76 IgA titers, but not IgG (14). Natural infection induces mucosal antibodies directed against S-
77 protein and RBD, and it has been suggested that higher antibody levels correlated with fewer
78 systemic symptoms and reduced viral load (16). Thus, respiratory mucosal immunity could have
79 unique and specific roles in offering protection against SARS-CoV-2 infection (17).

80
81 Secretory IgA (SIgA) is the most abundant immunoglobulin expressed on mucosal surface and
82 serves as the first line of defense against infection (14). SIgA in the upper respiratory tract is
83 from the IgA-secreting plasma cells (18). Whilst it is possible for systemic IgG-producing B
84 cells to contribute the IgG in the respiratory tract, circulating monomeric IgA cannot be readily
85 transported into secretions, suggesting that there are distinct systemic and mucosal responses to
86 SARS-CoV-2 (14). Currently little is known about the mucosal immunity induced by SARS-
87 CoV-2 vaccinations.

88
89 To date, one study has reported that mRNA vaccines induce detectable levels of salivary IgA and
90 IgG responses to the S-protein and RBD of SARS-CoV-2, but their capability for viral
91 neutralization are unknown (19). Determining whether or not current vaccines induce antibody
92 response in the mucosa, and if so, the duration and sustainability of any such response in the
93 context of concurrent data on systemic immunity from plasma samples of vaccinated individuals
94 can provide invaluable information that can help optimize the use of these vaccines in a range of
95 public health strategies and in different community settings.

96
97 The lack of sampling standardization and validation of the mucosal fluid measurements were the
98 major challenges in the past. Our recent work using nasal strips to collect nasal epithelial lining

99 fluid (NELF) in SARS-CoV-2 infected children and adults is non-invasive and facilitates the
100 collection of undiluted NELF for SARS-CoV-2 nucleoprotein gene detection (20). The same
101 method was adopted for the mucosal antibody analysis in the current study. With the possibility
102 that subjects vaccinated with mRNA vaccine could induce salivary IgA against SARS-CoV-2
103 protein, we hypothesize that it might also induce SARS-CoV-2 S-protein specific antibody in
104 other mucosal surfaces. Here, we compared the serological and mucosal immune responses after
105 vaccination with CoronaVac and Comirnaty with a particular focus on S1-specific IgA levels
106 detected and neutralization capacity in NELF and plasma.

107 **RESULTS**


108

109 **Demographic of the subjects**

110 Forty-two subjects were recruited in this study. The median age of all subjects was 41 years old
111 (range 21-74), 40.3% were male. Longitudinal measurements of vaccine induced S1-specific IgG
112 and IgA in serum and NELF at four time points (**Figure 1A**), 0 to 2 days before the first dose
113 (Baseline), 14±2 days after the first dose (V+D14), 7±2 days after the booster dose (B+D7) and
114 any time between 14 days after the booster dose and before 3 months after the first dose (**Figure**
115 **1A**) were conducted. The median age was significantly different in subjects from the two vaccine
116 groups, CoronaVac (n=10, median age 59) and Comirnaty (n=32, median age 39.5) ($p=0.0004$).
117 All subjects declared that they did not have known unprotected exposure to SARS-CoV-2
118 infected subjects. To ensure that the measurements of the change in SARS-CoV-2 specific
119 immunoglobulin levels were not due to active SARS-CoV-2 infection during the study period, all
120 the NELF samples were tested negative for the presence of SARS-CoV-2 nucleoprotein gene. As
121 a result of the limited number of CoronaVac subjects and the detected difference in age, fifteen
122 additional subjects who received CoronaVac were recruited for sampling at the 4th time point
123 (**Figure 1B**). Among them, 43 subjects completed the questionnaire after vaccination to report
124 any local or systemic events (**Supplementary Table 1**).

125

126



127

128 **Fig 1. Study design and demographics.**

129 (A) There were three standard sampling timepoints and one extended sampling timepoint (4th
 130 sampling) of biological sample collection: (i) 0 to 2 days before the first vaccination (Baseline),
 131 (ii) 14±2 days after the first vaccination (V+D14), (iii) 7±2 days after booster (B+D7) and (iv)
 132 any day between 14 days after booster and before 3 months after the first vaccination. (B)
 133 Subjects vaccinated with CoronaVac (n=10, pink table) and Comirnaty (n=32, grey table) were
 134 recruited and followed longitudinally, there was a significant difference in their age distributions
 135 ($p = 0.0004$, Mann Whitney test, two-tailed) and so fifteen extra subjects vaccinated with
 136 CoronaVac were recruited to enrich the data for the 4th timepoint.

137 **Comirnaty induced detectable immunoglobulin in NELF**

138 Among the ten subjects who have taken CoronaVac, none of them developed detectable NELF
139 SARS-CoV-2 S1-specific IgA and IgG (**Figure 2A**) by day 7 ± 2 days after booster, while most
140 subjects who received Comirnaty developed S1-specific antibodies. The elevations in S1-specific
141 IgA and IgG levels detected in NELF along the three time points were significant by two-way
142 ANOVA followed by Tukey's multiple comparisons test (**Figure 2D**). Moreover, S1-specific
143 IgA appeared earlier than IgG in NELF. More subjects developed NELF S1-specific IgA 15/32
144 (46.9%) than IgG 3/32 (9.4%) (**Supplementary Figure 1B, blue dots**) by 14 ± 2 days after the
145 first vaccination. The proportion of subjects who had received Comirnaty were positive for
146 NELF S1-specific IgA and IgG increased to 26/32 (81.3%) and 23/32 (71.9%), respectively, by
147 7 ± 2 days after the booster dose (**Supplementary Figure 1C, blue dots**).

148


149 **SARS-CoV-2 IgA appeared earlier than IgG in plasma**

150 In the CoronaVac group, plasma S1-specific IgA increased significantly by 14 ± 2 days after the
151 first vaccination dose and 7 ± 2 days after the booster dose (**Figure 2B, green dots**), while the
152 significant increase in S1-specific IgG was only detected between baseline and 7 ± 2 days after
153 booster (**Figure 2B, orange dots**). On 7 ± 2 days after booster, 7/10 (70%) of the CoronaVac
154 subjects had detectable plasma S1-specific IgG.

155 In the Comirnaty group (**Figure 2E**), 93.8% and 100% of subjects were positive for both plasma
156 S1-specific IgA and IgG by 14 ± 2 days after the first vaccination dose (**Supplementary Figure**
157 **1B, red dots**) and 7 ± 2 days after the booster dose (**Supplementary Figure 1C, red dots**),
158 respectively. The outliers were contributed by three subjects who were IgA-IgG+ (Subject 40),

159 IgA+IgG- (Subject 11) and IgA-IgG- (Subject 20). Nevertheless, all plasma samples were
160 IgA+IgG+ by 7 ± 2 days after booster.

161 There were no statistically significant correlations between age and the induced NELF and
162 plasma S1-specific IgA and IgG levels in the longitudinal CoronaVac and Comirnaty recipients
163 (**Supplementary Figure 2**). However, female subjects who received Comirnaty had higher
164 plasma S1-specific IgG at the 14 ± 2 days timepoint than male subjects ($p = 0.007$)
165 (**Supplementary Figure 2D**).



166
167 **Fig 2. Expression of NELF and plasma SARS-CoV-2 S1-specific IgA and IgG and**
168 **neutralizing antibody (NAb).**

169 The level of S1-specific IgA (green dots) and IgG (red dots) were plotted against the three
170 standard timepoints of sample collection in NELF (**A and D**) and plasma (**B and E**) specimens
171 of the recipients of CoronaVac (**A and B**) and Comirnaty (**D and E**). Data points above the
172 dotted line (Sample/Calibrator (S/C) ratio ≥ 1.1) are considered as positive, while the dotted lines
173 at $y=15$ indicate the upper detection limit of the assay. Asterisks indicate statistical significance
174 between timepoints of the same Ig class by two-way repeated-measures ANOVA followed by

175 Tukey's multiple comparison test. **: $p < 0.001$, ***: $p < 0.0002$ and ****: $p < 0.0001$. The
176 percentage of signal inhibition observed with the surrogate SARS-Co-V 2 neutralization
177 antibody detection kit by the NELF and plasma samples of CoronaVac (C) and Comirnaty (F)
178 recipients collected on 7 ± 2 days after booster were plotted. The 30% signal inhibition cutoff for
179 SARS-CoV-2 NAb detection is interpreted as the sample containing neutralizing antibodies for
180 SARS-CoV-2.


181 **Neutralization potential of NELF and plasma**

182 We further tested whether NELF and plasma samples were SARS-CoV-2 neutralizing by using
183 the blocking enzyme-linked immunosorbent assay as a surrogate of the neutralization test. NELF
184 and plasma samples collected at 7 ± 2 days after booster were measured. In the CoronaVac group,
185 as there were no SARS-CoV-2 S1-specific IgA and IgG detected in the NELF, we did not
186 perform NAb measurement for those samples. Whereas 7/10 of the plasma from CoronaVac
187 subjects contained SARS-CoV-2 NAb. In the Comirnaty group, 20/32 NELF samples inhibited
188 the binding of SARS-CoV-2 spike protein to ACE-2 (**Figure 2F**), whereas all plasma samples
189 provided over 80% inhibition to the binding of SARS-CoV-2 spike protein to ACE-2.

190

191 **The correlation between SARS-CoV-2 S1-specific Ig with neutralization antibody level**

192 In the CoronaVac group, no significant correlations were found between the plasma IgA and IgG
193 levels with the percentage of binding inhibition (**Figure 3A**). In the Comirnaty group, significant
194 correlations were found between the S/C ratio of NELF IgA ($r=0.509$, $p=0.031$), NELF IgG
195 ($r=0.777$, $p<0.0001$) (**Figure 3B**) and plasma IgA ($r = 0.634$, $p=0.008$) levels and the percentage
196 of binding inhibition (**Figure 3C**).



197

198 **Fig 3. Correlation of SARS-CoV-2 S1-specific Igs to the percentage of signal inhibition in**
199 **the surrogate ACE-2 based neutralization readout.**

200 The correlation coefficients of the S/C ratio of the (A) plasma of CoronaVac subjects, (B) NELF
201 and (C) plasma of Comirnaty subjects at 7 ± 2 days after booster are superimposed on the panel
202 with trend lines estimated with the use of simple linear regression. Plots show the S/C ratio of the
203 SARS-CoV-2 S1-specific IgA (green dots) and IgG (orange dots) between ≥ 1.1 to < 15 were
204 plotted against the percentage of inhibition of the SARS-CoV-2 Spike-ACE-2 binding signal, in
205 which an inhibition $\geq 30\%$ is regarded as the threshold of a positive sample, indicated by the
206 vertical dotted line. Data with negative result in either one test were excluded from the two-tailed
207 Spearman correlation analysis. Green and orange dotted lines represent significant linear
208 regression fits with 95% confidence intervals (shaded region with the corresponding colors).

209 **Neutralizing antibody in NELF is transient**


210 Whether this is a transient expression SARS-CoV-2 NAb in NELF is uncertain, as there were
211 five individuals (subjects 9, 33, 34, 37, 41) showing a downward trend of S/C ratio of IgA from
212 14 ± 2 days after the first vaccination to 7 ± 2 days after booster (**Supplementary Figure 2A**). The
213 longevity of the NAb in NELF was further assessed in 11/32 Comirnaty subjects who had
214 reached the 4th sampling time point, i.e. any time after 14 days post-booster and before 3 months
215 post-vaccine (**Figure 4A**). Only three NELFs still contained NAb, while two of them became
216 NAb negative. Nevertheless, a late NELF NAb development was observed in two individuals,
217 who did not possess NELF NAb earlier on 7 ± 2 days after booster, though four subjects' NELF
218 remained negative for NAb. Within these eleven subjects, a significant decrease in the S/C ratio
219 of the S1-specific IgA was also observed from 7 ± 2 days after booster to the 4th sampling time
220 point ($p=0.018$) (**Supplementary Figure 3**). Lastly, at the 4th sampling time point, the 25
221 NELFs obtained from the CoronaVac group also underwent the NAb assay, however, none of
222 them were positive, though one subject from the cross-sectional group had a positive S1-specific
223 IgA (S/C ratio=1.27) readout.

224

225 **75% NAb detection in CoronaVac subjects' plasma**

226 After 7 ± 2 days of the booster 7/10 subjects who had received CoronaVac had NAb (**Figure 4B**),
227 and five of them remained NAb positive by their 4th sampling time point. With the extended
228 time after booster, one gained NAb by 24 days after the booster (subject 13) though another
229 subject did not develop plasma NAb even by 20 days post booster (Subject 14). The differences
230 in observations in our longitudinal cohort of Sinovac recipients (n=9) from Comirnaty recipients
231 were unlikely an age effect, as we found that consistent with the longitudinal subjects, 12/15

232 plasma samples from the younger subjects in the cross-sectional group of CoronaVac recipients
233 had NAb (**Figure 4B, pink dots**). Overall, 75% (18/24) of the recruited subjects had NAb in
234 their plasma at the 4th sampling time point. Moreover, there were no correlations between NAb
235 levels either with time post booster ($p=0.38$) or with age ($p=0.78$). In the Comirnaty group, all
236 subjects had NAb since 7 ± 2 days after booster and it lasted at least for 50 days after the booster
237 dose (**Figure 4C**).



238

239 **Fig 4. Longevity of the NAb in NELF and plasma samples.**

240 (A) The paired-percentage of signal inhibition by the NAb in the NELF from 7 ± 2 days after
241 booster to the 4th sampling time point of eleven Comirnaty subjects. Data from the samples of
242 the same individual is joined by a dotted line. (B) The paired-percentage of signal inhibition by
243 NAb in the plasma from 7 ± 2 days after booster to the 4th sampling time point of CoronaVac
244 subjects in the longitudinal group ($n=9$, red dots) is joined by a dotted line, and each pink dot
245 represents the percentage of signal inhibition of the plasma samples from CoronaVac recipients
246 in the cross-sectional group ($n=15$). (C) The paired-percentage of signal inhibition by NAb in the
247 plasma of eleven Comirnaty subjects from 7 ± 2 days after booster to the 4th sampling time point
248 is shown.

249

250 **DISCUSSION**

251 Our study reveals that both Comirnaty and CoronaVac induces plasma SARS-CoV-2 S1-specific
252 IgA and IgG, and NAb. However, Comirnaty, but not CoronaVac, induced S1-specific IgA and
253 IgG in the nasal mucosa by 7 ± 2 days after booster. Of the Comirnaty recipients 72% produced
254 an NELF antibody response, while 62.5% exhibited neutralizing activities in their NELF
255 samples. The NAb in NELF correlated with the S/C ratio of the S1-specific IgA and IgG
256 detected. The induction of nasal S1-specific Igs and NAb is unique to subjects receiving
257 Comirnaty and it was not found in the NELF of the CoronaVac recipients. The longevity of the
258 NAb in NELF was assessed in 12/32 Comirnaty subjects who had reached the extended time
259 point, i.e. any day between 14 days after booster and before 3 months after the first vaccination.
260 Only three NELFs remained neutralizing, while two of them became NAb negative.
261 Nevertheless, a late rise in NELF NAb was observed in two individuals who did not possess
262 NAb in their NELF in the earlier time points. Lastly, four of the Comirnaty recipients remained
263 NELF NAb negative through all timepoints. From our data, the plasma NAb may last at least 50
264 days after the booster, though further samples are required to validate this claim.

265
266 It has been commonly believed that intramuscular vaccines do not induce mucosal immunity
267 effectively (21). The mucosal immune response of the upper respiratory tract is partly
268 compartmentalized and usually initiated in nasopharynx-associated lymphoid tissue (NALT) in
269 all age groups and bronchus-associated lymphoid tissue (BALT) in children and adolescents or
270 in adults upon disease induction (18). These upper respiratory tract associated lymphoid tissues
271 generate IgA-producing mucosal B cells that express the homing receptor, e.g. $\alpha 4\beta 1$, CCR10,
272 CD62L and LFA-1 (22, 23). These homing receptors allow the B-cells to traffic efficiently to the

273 mucosal effector site, the respiratory tract in this case, where their ligands VCAM-1 and CCL28
274 are strongly expressed. The IgA-producing mucosal B cells differentiate into polymeric IgA-
275 secretory plasma cells and contribute to the production of the polymeric IgA (in dimers or
276 tetramers) in the lamina propria as opposed to serological IgA (predominantly monomers), which
277 is produced within bone marrow, spleen and lymph nodes (17). Therefore, SIgA present in
278 secretions are typically produced within mucosal tissues. This raises important questions about
279 the route that mRNA-lipid nanoparticles would take from the intramuscular injection site to the
280 NALT (and BALT) and the biological mechanisms that underlie this process.

281
282 In an animal study using similar lipid nanoparticles carrying mRNA encoding haemagglutinin
283 proteins of influenza to investigate the biodistribution of the influenza mRNA in mouse plasma
284 and tissue after intramuscular administration. It is assumed that the concentration of mRNA lipid
285 nanoparticles decreases along the disseminating route from the injection site which includes
286 through the systemic circulation and via the lymphatic system, spleen and liver. It was found that
287 the expression of mRNA can be detected in distal tissues, including lung, though the
288 concentration was 1,000 fold lower (24). The same study also showed the presence of mRNA in
289 the intestine, though they did not test for the presence of such in the airway mucosae. In terms of
290 the Comirnaty vaccine, the 30-microgram vaccine dose contains approximately 13,000 billion
291 repetitions of the optimized SARS-CoV-2 Spike protein sequence as documented (2). We
292 postulate that the number of the mRNA lipid-nanoparticles that reach the nasal mucosa after
293 Comirnaty injection might be sufficient for NALT stimulation. However, the mechanisms
294 underlying this process and factors that affect the consistency of this effect requires further
295 investigation.

296

297 The clinical implication of the induction of nasal SARS-CoV-2 NAb is increased likelihood of
298 immediate protection at the target site of viral infection. The role that this mucosal immune
299 response may play in reducing the risk of virus transmission should also be considered.
300 Sufficiently high concentrations of NAb in the NELF can block the attachment of virus to the
301 host cell receptor. The SIgA is known to trap virus efficiently and facilitates the removal of such
302 by the mucociliary beating (25), to neutralize virus particles with epithelial cell and lamina
303 propria (17), and has anti-inflammatory properties (26).

304

305 We also confirmed the presence of vaccination induced plasma S1-specific IgA and IgG in both
306 CoronaVac and Comirnaty recipients. For CoronaVac, 70% of the subjects were found to have
307 NAb by 7 ± 2 days after booster. Whereas all subjects who received two doses of Comirnaty had
308 NAb in their plasma samples 7 ± 2 days after booster. Of note, at the 4th sampling time point,
309 73% of the cross-sectional CoronaVac group had plasma NAb (**Figure 4A**, pink dots), which is
310 similar to the older subjects in the longitudinal CoronaVac group, inferring that age is not a
311 contributing factor to the NAb level in the CoronaVac group. Therefore, the lower percentage of
312 plasma NAb detected in CoronaVac than the Comirnaty group cannot simply be explained by the
313 difference in age.

314

315 The delayed NAb response found in CoronaVac subjects compared with those in Comirnaty
316 group was not surprising. It has been reported that seroconversion rates were 47.8% and 95.6%
317 for S1-RBD-specific IgG for CoronaVac at 14 days and 28 days after booster, respectively (9).
318 Thus, our study design with this interim report at 7 days \pm 2 post booster may not have

319 demonstrated the full immune responses elicited by CoronaVac. Nevertheless, there were seven
320 CoronaVac subjects who did not develop NAb in their plasma samples even by the 4th sampling
321 time point. Three of them were from the longitudinal group in which two of them had their NAb
322 weaned on 55 and 56 days after booster (Subjects 8 and 5, respectively) while one of them never
323 exhibited plasma NAb even after 19 days of booster (Subject 14). For the four NAb negative
324 plasma results contributed by the cross-sectional group, without the baseline measurements, we
325 cannot conclude whether this was due to a short duration of their NAb responses or if they never
326 developed a NAb response. The apparent non-responders were subjects L7, L25, L37 and L38 at
327 their 55, 51, 39 and 25 days after booster, respectively. This might infer the needs of an
328 additional dose to ensure a sufficient protection to the CoronaVac recipients (27). Moreover,
329 apart from the humoral response towards spike protein, the development of antibodies against
330 other viral proteins which have a lower mutation rate, such as nucleoprotein, might be an edge of
331 CoronaVac over Comirnaty (28). Furthermore, a comprehensive measurement to include the
332 cellular response induction would provide a balanced information about the overall protection
333 against SARS-CoV-2 exerted by vaccination (29).

334
335 Consistent with our findings, Danese *et al.* demonstrated that all SARS-CoV-2 antibodies (IgM,
336 IgG, IgA) begin to rise from 7 to 11 days post primer dose of Comirnaty and they also showed
337 that the booster dose of Comirnaty further increases the levels of IgG against S1/S2 and RBD
338 (13). Both plasma IgG and IgA levels have been found to remain elevated for up to 65 days post
339 first vaccine dose (13). Whilst Wang *et al.* reported that after receiving two doses of mRNA
340 vaccines (Comirnaty or Moderna), high levels of IgM and IgG against S and RBD of SARS-
341 CoV-2 is detectable for up to 8 weeks after booster (11). Furthermore, our study demonstrated

342 the correlation between plasma IgA levels with the percentage of virus-receptor binding
343 inhibition as reported in a previous study (14). Together, our findings confirm the reliability of
344 Comirnaty in generating robust humoral immune responses in vaccinated subjects.

345
346 The presence of nasal mucosal immunoglobulins after vaccination against COVID-19 has not
347 been previously reported. Whilst we currently have some insights into the durability of
348 serological IgA and IgG response after Comirnaty vaccination. There is currently no information
349 on the longitudinal expression of the immunoglobulins in NELF samples representing mucosal
350 immunity in COVID-19 patients nor recipients of SARS-CoV-2 vaccine. We are now
351 continuously following these subjects and collecting paired NELF and blood samples at 3, and 6
352 months after first dose of vaccination to better understand the longevity of mucosal immunity
353 elicited by intramuscular vaccination. Such findings could have implications on public health
354 strategies and screening for immunity to enable resumption of normalcy on a global scale.

355
356 The current study has the following limitations. First, the smaller sample size and the higher
357 median age of the recipients of CoronaVac in the longitudinal group can be argued to have
358 contributed towards the absence in NELF response and a slower and milder plasma response
359 when compared to Comirnaty. We attempted to recruit the cross-sectional subjects to enrich our
360 data for this important early report, while more subjects would be recruited for a better
361 comparison. Second, we were using a SARS-CoV-2 surrogate virus neutralization test instead of
362 a neutralization assay with live cells and viruses in Biosafety Level 3 settings. Therefore, the
363 NAb measured in this study is a surrogate measure that is solely based on the inhibition of the
364 binding between the SARS-CoV-2 antibody-mediated blockage of ACE2-spike (RBD) protein-

365 protein interaction (30). The protective effects of the intracellular action of NELF IgA in the
366 Comirnaty recipients or the plasma Ig specific to other SARS-CoV-2 proteins that theoretically
367 should be manufactured in CoronaVac recipients were not considered. Although the surrogate
368 assay used has been validated with the plaque reduction neutralization test (PRNT) utilizing the
369 SARS-CoV-2 virus (31), the current test could underestimate the actual neutralization capacity.
370 Third, we observed tremendous individual variations, for example, some recipients of Comirnaty
371 were found to be IgA-, IgG- or IgA-IgG- for S1 protein. Although Comirnaty induced mucosal
372 immunoglobulins for 72% of vaccinated subjects, there were individuals who, despite having
373 plasma S1-specific IgA and IgG, did not express NELF S1-specific IgA (n=2) or IgG (n=5) or
374 both (n=4). These variations require a larger sample size to further clarify. Nevertheless, our
375 current study clearly shows qualitative and significant differences in mucosal response between
376 different vaccine technologies. Lastly, the best available assay for the measurement of SARS-
377 CoV-2 S1-specific IgA and IgG used in this study was optimized for plasma and serum rather
378 than mucosal lining fluid. We were therefore unable to differentiate between the monomeric and
379 dimeric forms of IgA or identify any secretory component in our subjects' NELF samples.

380

381 **CONCLUSION**

382 Despite being a vaccine administered via the intramuscular route, Comirnaty, and likely other
383 mRNA vaccines, uniquely induces SARS-CoV-2 S1 specific IgA and IgG in the nasal mucosal
384 of vaccine recipients as early as 14 days after the first dose. The NELF neutralizing effect infers
385 protection from SARS-CoV-2 infection at the level of the upper respiratory epithelium, when the
386 level of NAb is sufficiently high. This extra arm of protection at the mucosa, on top of the well-
387 characterized serological antibody development, might further reduce the chance of SARS-CoV-

388 2 infection, in addition to its effectiveness in protecting the recipient from hospitalization and
389 severe disease. Though the response may be transient, it is possible that a more rapid elevation in
390 antibodies may occur within the mucosa when the subject is exposed to live viruses, thus
391 conferring protection from infection even before the virus breaches the mucosa. CoronaVac
392 vaccine induces an IgG dominant response in the recipients' plasma with neutralizing effect, but
393 did not produce any mucosal antibody response. The duration required for the plasma Igs and
394 NAb development observed in our study, is comparable to what has been previously reported,
395 however, the additional information relating to mucosal response and the direct comparison
396 between two vaccine technologies provides important insights into how to best utilize these
397 different vaccines from a public health point of view.

398

399 **IMPLICATIONS**

400 This study provides paired data of the mucosal findings and systemic immunological endpoints
401 of adults before and after receiving the two different SARS-CoV-2 vaccines. The insights gained
402 from the different immune profiles between inactivated viral vaccines and mRNA vaccines
403 would be helpful to help optimize public health strategies. While we found that both Comirnaty
404 and CoronaVac induced systemic humoral responses, Comirnaty likely provides enhanced
405 mucosal level immune protection and which we postulate could contribute to reduction in
406 asymptomatic transmission risk. This suggests that Comirnaty may be more suitable for
407 individuals who are often in close contact with vulnerable and/or unvaccinated individuals (e.g.,
408 old age home workers, pediatricians, school teachers).

409

410 CoronaVac, on the other hand, induced satisfactory systemic humoral response with neutralizing
411 capacity induced by CoronaVac in most individuals, and there is less concern about the potential
412 for unintended inflammatory or immune reactions in organs/tissues distal to the vaccination site
413 means that CoronaVac may be more suitable for large groups of vulnerable populations who
414 require protection from SARS-CoV-2. The easier logistics involves in the storage and
415 distribution of CoronaVac might help to provide a high vaccination coverage within such
416 vulnerable populations.

417 The unexpected mucosal response in mRNA vaccine recipients raises the concern about which
418 other organs/tissues may be similarly affected and whether inflammatory/immunological
419 responses in some tissues may cause unintended side effects with adverse outcomes. Therefore,
420 this piece of information highlights the necessity in speeding up further studies to determine the
421 distribution of mRNA lipid nanoparticles in humans. Moreover, the mucosal humoral response
422 against SARS-CoV-2 S protein is inconsistent between individuals. The publication of this
423 manuscript will consolidate the collaborative effort among different research groups to
424 investigate the biological determinant to increase the consistency of mucosal response.

425 Finally, we see a niche for the further development of the antibody detection strategy by using
426 mucosal lining fluid sample. The current collection method is painless, self-administered and can
427 be carried out repeatedly in all age groups. The mucosal antibody test would provide the immune
428 status after vaccination (or by natural infection), with a direct reflection of the protection level at
429 the site of virus entry.

430 **MATERIALS AND METHODS**

431 *Subject recruitment*

432 We released the information of this study through the department website, department social
433 media, The Chinese University of Hong Kong (CUHK) mass mail system, CUHK-online form
434 and word of mouth to reach potential subjects and arrange the sampling logistics. Subject who
435 had arranged their own COVID-19 vaccinations with known schedules of vaccine doses were
436 recruited. All subjects were requested to complete a one-page questionnaire to capture their
437 demographics, past medical history, drug use and the reporting of any adverse effects after
438 vaccination or respiratory tract infections within the study period. Consent was obtained from the
439 participants and the study was approved by the Joint Chinese University of Hong Kong – New
440 Territories East Cluster Clinical Research Ethics Committee (CREC: 2021.214).

441

442 *Clinical sample collection regime*

443 Nasal lining epithelial lining fluid (NELF) from both nares and 3mL peripheral blood were
444 collected from the subjects at four time points. A pre-vaccination sample pair was collected
445 during the 48-hour period before the day of vaccination. Three post-vaccination sample pairs
446 were collected at 14 ± 2 days after first dose and 7 ± 2 days post-booster as in **Figure 1A**. An
447 extended sampling timepoint (4th sampling) of biological sample collection was performed any
448 day between 14 ± 2 days after the booster and before 3 months after the first vaccination dose, to
449 assess the intermediate longevity of SARS-CoV-2 specific Ig and NAb responses.

450

451 *NELF collection by nasal strips*

452 Strips were cut from sheets of Leukosorb medium (Pall Corporation, BSP0669) using a laser
453 cutter (CMA960, Department of Biomedical Engineering, CUHK) to the dimensions of 4 mm
454 wide and 40mm long with a marking at 12mm as previously described (20, 32). 100uL of sterile
455 saline were instilled in each nostril of the subject. Strips were inserted into the anterior part of the
456 inferior nasal turbinate of each nostril until the indicator mark was at or close to the base of each
457 naris. After insertion, the nose was pinched for 1 minute to allow thorough absorption of NELF
458 by the strip. Strips were removed and eluted within 24h after collection. To elute NELF, strips
459 were soaked in 300uL PBS on ice for 5 min with a quick vortex. The solution and the strip were
460 transferred to a Costar Spin-X (CLS9301) and centrifuged twice at 13,000 rpm for 2 min at 4°C
461 to elute the NELF from the strip into the 1.5-ml tube. The NELF was aliquoted into small
462 volume vials for downstream analysis of SARS-CoV-2 specific Ig panels and neutralization test
463 and were stored at -80°C until analysis.

464

465 *Plasma preparation*

466 Blood was collected aseptically by venepuncture and transferred into EDTA blood tube. Plasma
467 samples were separated by centrifugation at 4°C, 2000g for 20 minutes, aliquoted into small
468 volume specimens and stored at -20° C until analysis.

469

470 *Measurement of specific IgA and IgG against SARS-CoV-2 Spike protein*

471 Semi-quantitative measurements of SARS-CoV-2 Spike protein (S1 domain) specific Ig ELISA
472 Kits (Euroimmun, EI 2606-9601 A and EI 2606-9601 G) were used. 1:10 diluted-NELF and
473 1:100 diluted plasma were added to the assay well and processed as per manufacturer's
474 instructions. After subsequent wash and incubation steps with conjugates or substrates, the

475 plates were analyzed according to the manufacturer's instructions on the Synergy HTX Multi-
476 Mode Reader. Semi-quantitative readout as a ratio between the sample and the calibrator optical
477 density (OD) values was used. The performance was checked by keeping the optical density of
478 the calibrator within the reference value, and the ratio between the positive and negative controls
479 between 1.6-4.2 and 0-0.7, respectively.

480

481 *Measurement of SARS-CoV-2 neutralization antibody*

482 A blocking enzyme-linked immunosorbent assay (GenScript, L00847) was employed. Briefly,
483 NELF, plasma samples and controls were 1:9 diluted and mixed with HRP-RBD solution and
484 incubated at 37°C for 30 minutes. The mixture was then added to the human ACE-precoated
485 plate and incubated at 37°C for 15 minutes and processed as per manufacturer's instructions. The
486 performance was checked by ensuring that the OD450 must fall below 0.3 for the positive
487 control and above 1.0 for the negative control. A 30% signal inhibition was set as the cutoff for
488 SARS-CoV-2 NAb detection.

489

490 *Viral RNA extraction and quantification*

491 To eliminate the possibility of active SARS-CoV-2 infection during the study period, 70uL of
492 NELF collected at each timepoint were extracted using PHASIFY VIRAL RNA Extraction
493 Kit™ following manufacturer's instruction. RNA was reconstituted in 20uL of RNase-free
494 water. 4uL of the RNA sample was used in each reaction, and the SARS-CoV-2 RNA was
495 quantified by one-step Master Mix (TaqMan Fast Virus, ThermoFisher) with primers and probe
496 targeting the N gene of SARS-CoV-2 as described (33). Duplicate reaction was conducted on
497 QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) at

498 the following cycling conditions: reverse transcription at 50°C for 5 min, inactivation of reverse
499 transcriptase at 95°C for 20s, 40 cycles of PCR amplification (Denaturing at 95°C for 5s;
500 Annealing/ Extending at 60°C for 30s). No template control and positive control using cell
501 lysate from SARS-CoV-2 infected human respiratory cells were included in each run.

502

503 *Statistical analysis*

504 The demographic variables of subjects were compared between the two vaccinated groups using
505 the Mann Whitney test and Fisher's exact test, as appropriate. For the immunoglobulin profiles,
506 differences between different gender and time points were evaluated using Mann Whitney test
507 and Friedman test followed by Dunn's multiple comparison test, respectively. The correlation of
508 S/C ratio of the specific immunoglobulins with the percentage of signal inhibition in the
509 surrogate neutralization test was examined by Spearman's correlation test. Differences were
510 considered to be statistically significant if $p < 0.05$. The All statistical tests were performed using
511 Graphpad version 9.1.2 for macOS. Differences were considered statistically significant at $p <$
512 0.05.

References

1. WHO Coronavirus (COVID-19) Dashboard (2021 <https://covid19.who.int>).
2. *Messenger RNA encoding the full-length SARS-CoV-2 spike glycoprotein.* (11889, 2020).
3. L. Dai, G. F. Gao, Viral targets for vaccines against COVID-19. *Nat Rev Immunol* **21**, 73-82 (2021).
4. M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**, 562-569 (2020).
5. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U. Jansen, W. C. Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
6. Z. Wu, Y. Hu, M. Xu, Z. Chen, W. Yang, Z. Jiang, M. Li, H. Jin, G. Cui, P. Chen, L. Wang, G. Zhao, Y. Ding, Y. Zhao, W. Yin, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*, (2021).
7. Y. Zhang, G. Zeng, H. Pan, C. Li, Y. Hu, K. Chu, W. Han, Z. Chen, R. Tang, W. Yin, X. Chen, Y. Hu, X. Liu, C. Jiang, J. Li, M. Yang, Y. Song, X. Wang, Q. Gao, F. Zhu, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in

- healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181-192 (2021).
8. R. a. B. Palacios, Ana Paula and Albuquerque, Camila Santos Nascimento and Patiño, Elizabeth González and Santos, Joane do Prado and Tilli Reis Pessoa Conde, Mônica and Piorelli, Roberta de Oliveira and Pereira Júnior, Luiz Carlos and Raboni, Sonia Mara and Ramos, Fabiano and Sierra Romero, Gustavo Adolfo and Leal, Fábio Eudes and Camargo, Luis Fernando Aranha and Aoki, Francisco Hideo and Coelho, Eduardo Barbosa and Oliveira, Danise Senna and Fontes, Cor Jesus Fernandes and Pileggi, Gecilmara Cristina Salviato and Oliveira, Ana Lúcia Lyrio de and Siqueira, André Machado de and Oliveira, Danielle Bruna Leal de and Botosso, Viviane Fongaro and Zeng, Gang and Xin, Qianqian and Teixeira, Mauro Martins and Nogueira, Maurício Lacerda and Kallas, Esper Georges, Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study (April 11, 2021). (2021).
9. S. M. Bueno, K. Abarca, P. A. González, N. M. Gálvez, J. A. Soto, L. F. Duarte, B. M. Schultz, G. A. Pacheco, L. A. González, Y. Vázquez, M. Ríos, F. Melo-González, D. Rivera-Pérez, C. Iturriaga, M. Urzúa, A. Dominguez, C. A. Andrade, R. V. Berrios, G. Canedo-Marroquín, C. Covián, D. Moreno-Tapia, F. Saavedra, O. P. Vallejos, P. Donato, P. Espinoza, D. Fuentes, M. González, P. Guzmán, P. Muñoz-Venturelli, C. M. Pérez, M. Potin, A. Rojas, R. Fasce, J. Fernández, J. Mora, E. Ramírez, A. Gaete-Argel, A. Oyarzún-Arrau, F. Valiente-Echeverría, R. Soto-Rifo, D. Weiskopf, A. Sette, G. Zeng, W. Meng, J. V. González-Aramundiz, A. M. Kalergis, Interim report: Safety and

- immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. *medRxiv*, 2021.2003.2031.21254494 (2021).
10. U. Sahin, A. Muik, I. Vogler, E. Derhovanessian, L. M. Kranz, M. Vormehr, J. Quandt, N. Bidmon, A. Ulges, A. Baum, K. E. Pascal, D. Maurus, S. Brachtendorf, V. Lorks, J. Sikorski, P. Koch, R. Hilker, D. Becker, A. K. Eller, J. Grutzner, M. Tonigold, C. Boesler, C. Rosenbaum, L. Heesen, M. C. Kuhnle, A. Poran, J. Z. Dong, U. Luxemburger, A. Kemmer-Bruck, D. Langer, M. Bexon, S. Bolte, T. Palanche, A. Schultz, S. Baumann, A. J. Mahiny, G. Boros, J. Reinholz, G. T. Szabo, K. Kariko, P. Y. Shi, C. Fontes-Garfias, J. L. Perez, M. Cutler, D. Cooper, C. A. Kyratsous, P. R. Dormitzer, K. U. Jansen, O. Tureci, BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. *Nature*, (2021).
 11. Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West, K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J. Dizon, C. Unson-O'Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J. Bjorkman, R. Casellas, T. Hatzioannou, P. D. Bieniasz, M. C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* **592**, 616-622 (2021).
 12. Y. X. Chao, O. Rotzschke, E. K. Tan, The role of IgA in COVID-19. *Brain Behav Immun* **87**, 182-183 (2020).
 13. E. Danese, M. Montagnana, G. L. Salvagno, D. Peserico, L. Pighi, S. De Nitto, B. M. Henry, S. Porru, G. Lippi, Comprehensive assessment of humoral response after Pfizer

- BNT162b2 mRNA Covid-19 vaccination: a three-case series. *Clin Chem Lab Med*, (2021).
14. D. Sterlin, A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Claer, P. Quentric, J. Fadlallah, H. Devilliers, P. Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot, C. E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Bruel, O. Schwartz, J. M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, G. Gorochoy, IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med* **13**, (2021).
 15. N. Dagan, N. Barda, E. Kepten, O. Miron, S. Perchik, M. A. Katz, M. A. Hernan, M. Lipsitch, B. Reis, R. D. Balicer, BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* **384**, 1412-1423 (2021).
 16. J. Fröberg, J. Gillard, R. Philipsen, K. Lanke, J. Rust, D. van Tuijl, T. Bousema, E. Simonetti, C. E. van der Gaast – de Jongh, M. Bos, F. J. van Kuppeveld, B.-J. Bosch, M. Nabuurs-Franssen, N. van der Geest-Blankert, C. van Daal, M. A. Huynen, M. I. de Jonge, D. A. Diavatopoulos, Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms. *medRxiv*, 2021.2002.2002.21250910 (2021).
 17. M. W. Russell, Z. Moldoveanu, P. L. Ogra, J. Mestecky, Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. *Front Immunol* **11**, 611337 (2020).
 18. T. Tschernig, R. Pabst, Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. *Pathobiology* **68**, 1-8 (2000).
 19. T. J. Ketas, D. Chaturbuj, V. M. Cruz-Portillo, E. Francomano, E. Golden, S. Chandrasekhar, G. Debnath, R. Diaz-Tapia, A. Yasmeen, W. Leconet, Z. Zhao, P. J. M.

- Brouwer, M. M. Cushing, R. W. Sanders, A. Cupo, P. J. Klasse, S. C. Formenti, J. P. Moore, Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. *bioRxiv*, (2021).
20. R. W. Y. Chan, K. C. Chan, K. Y. Y. Chan, G. C. Y. Lui, J. G. S. Tsun, R. Y. K. Wong, M. W. L. Yu, M. H. T. Wang, P. K. S. Chan, H. S. Lam, A. M. Li, SARS-CoV-2 detection by nasal strips: A superior tool for surveillance of paediatric population. *J Infect* **82**, 84-123 (2021).
21. B. Zheng, W. Peng, M. Guo, M. Huang, Y. Gu, T. Wang, G. Ni, D. Ming, Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. *Chem Eng J* **418**, 129392 (2021).
22. B. Xu, N. Wagner, L. N. Pham, V. Magno, Z. Shan, E. C. Butcher, S. A. Michie, Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways. *J Exp Med* **197**, 1255-1267 (2003).
23. F. E. Johansen, E. S. Baekkevold, H. S. Carlsen, I. N. Farstad, D. Soler, P. Brandtzaeg, Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. *Blood* **106**, 593-600 (2005).
24. K. Bahl, J. J. Senn, O. Yuzhakov, A. Bulychev, L. A. Brito, K. J. Hassett, M. E. Laska, M. Smith, O. Almarsson, J. Thompson, A. M. Ribeiro, M. Watson, T. Zaks, G. Ciaramella, Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. *Mol Ther* **25**, 1316-1327 (2017).

25. J. Froberg, D. A. Diavatopoulos, Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. *Curr Opin Infect Dis* **34**, 181-186 (2021).
26. Russell MW, Kilian M, Mantis NJ, C. s. B, in *Mucosal Immunology*. (New York, 2015), vol. 1.
27. Global Times, Sinovac says a booster shot for COVID-19 would increase antibody response tenfold within one week. *Global Times*, (2021).
28. L. Bochnia-Bueno, S. M. De Almeida, S. M. Raboni, D. Adamoski, L. L. M. Amadeu, S. Carstensen, M. B. Nogueira, SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days. *medRxiv*, 2021.2005.2020.21255825 (2021).
29. K. Murugesan, P. Jagannathan, T. D. Pham, S. Pandey, H. F. Bonilla, K. Jacobson, J. Parsonnet, J. R. Andrews, D. Weiskopf, A. Sette, B. A. Pinsky, U. Singh, N. Banaei, Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. *Clin Infect Dis*, (2020).
30. C. W. Tan, W. N. Chia, X. Qin, P. Liu, M. I. Chen, C. Tiu, Z. Hu, V. C. Chen, B. E. Young, W. R. Sia, Y. J. Tan, R. Foo, Y. Yi, D. C. Lye, D. E. Anderson, L. F. Wang, A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **38**, 1073-1078 (2020).
31. E. J. Valcourt, K. Manguiat, A. Robinson, J. C. Chen, K. Dimitrova, C. Philipson, L. Lamoureux, E. McLachlan, Z. Schiffman, M. A. Drebot, H. Wood, Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis* **99**, 115294 (2021).

32. M. E. Rebuli, A. M. Speen, P. W. Clapp, I. Jaspers, Novel applications for a noninvasive sampling method of the nasal mucosa. *Am J Physiol Lung Cell Mol Physiol* **312**, L288-L296 (2017).
33. D. K. W. Chu, Y. Pan, S. M. S. Cheng, K. P. Y. Hui, P. Krishnan, Y. Liu, D. Y. M. Ng, C. K. C. Wan, P. Yang, Q. Wang, M. Peiris, L. L. M. Poon, Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem* **66**, 549-555 (2020).

Acknowledgments

We would like to acknowledge Prof Aaron HP Ho, Prof Megan YP Ho and Miss Yuan-yuan Wei (Department of Biomedical Engineering, Faculty of Engineering, The Chinese University of Hong Kong) who tailor-cut the nasal strips for this study and Ms Fiona Cheng (Department of Paediatrics, The Chinese University of Hong Kong) for her assistance in preparing all the nasal strip vials. We would like to offer our special thanks to Ms Carrie Lee and Ms Cecily Leung in collecting the biospecimens from our research subjects and all the subjects who agreed to participate in this study. We thank Dr Agnes Leung, Prof Tony Nelson and Prof Ellis KL Hon (Department of Paediatrics, The Chinese University of Hong Kong) for their continuous encouragement to the research team.

Funding

Health and Medical Research Fund commissioned grants COVID190112 (RWYC)
The Chinese University of Hong Kong Direct Grant for Research 2020.075 (RWYC)
Hong Kong Institute of Allergy Research Grant 2020 (RWYC)

Author contributions

Conceptualization: KYYC, HSL, RWYC
Methodology: SL, JGST, KYYC, HSL, RWYC
Investigation: SL, JGST, KCCC, KYYC, GPGF, HSL, RWYC
Visualization: SL, JYC, JGST, KYYC, RWYC
Funding acquisition: HSL, AML, RWYC
Project administration: SL, JGST, KYYC, RWYC
Supervision: KYYC, HSL, AML, RWYC
Writing – original draft: SL, JYC, RWYC
Writing – review & editing: KCCC, KYYC, HSL, AML, RWYC

Competing interests: The authors have no competing interests.